SalaryGuide
AboutPricingFor Employers

Marketing jobs

5 marketing jobs

Otsuka Pharmaceutical Companies (U.S.) logo
2 months ago

Executive Director, Omnichannel & Content Operations

Otsuka Pharmaceutical Companies (U.S.)

Princeton, NJ (On-site)Full time$250K/yr – $388K/yr
Otsuka Pharmaceutical Companies (U.S.) logo
2 months ago

Director, Internal and Executive Communications

Otsuka Pharmaceutical Companies (U.S.)

Princeton, NJ (On-site)Full time$186K/yr – $279K/yr
Otsuka Pharmaceutical Companies (U.S.) logo
2 months ago

Executive Director, US Access Strategy & Marketing, CNS

Otsuka Pharmaceutical Companies (U.S.)

USA (Hybrid)Full time$250K/yr – $388K/yr
Otsuka Pharmaceutical Companies (U.S.) logo
2 months ago

Director, HCP Marketing

Otsuka Pharmaceutical Companies (U.S.)

Princeton, NJ (On-site)Full time$186K/yr – $279K/yr
Otsuka Pharmaceutical Companies (U.S.) logo
4 months ago

Associate Director, Brand Analytics, CNS Pipeline

Otsuka Pharmaceutical Companies (U.S.)

Princeton, NJ (On-site)Full time$169K/yr – $253K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
Otsuka Pharmaceutical Companies (U.S.) logo

Executive Director, Omnichannel & Content Operations

Otsuka Pharmaceutical Companies (U.S.)

Princeton, NJ (On-site)

$250K/yr - $388K/yrIn-houseFull-timeSenior level12+ years exp.
2 months ago
Otsuka Pharmaceutical Companies (U.S.) logo

Director, Internal and Executive Communications

Otsuka Pharmaceutical Companies (U.S.)

Princeton, NJ (On-site)

$186K/yr - $279K/yrIn-houseFull-timeDirector/executive12+ years exp.
2 months ago
Otsuka Pharmaceutical Companies (U.S.) logo

Executive Director, US Access Strategy & Marketing, CNS

Otsuka Pharmaceutical Companies (U.S.)

USA (Hybrid)

$250K/yr - $388K/yrIn-houseFull-timeSenior level12+ years exp.
2 months ago
Otsuka Pharmaceutical Companies (U.S.) logo

Director, HCP Marketing

Otsuka Pharmaceutical Companies (U.S.)

Princeton, NJ (On-site)

$186K/yr - $279K/yrIn-houseFull-timeDirector/executive8+ years exp.
2 months ago
Otsuka Pharmaceutical Companies (U.S.) logo

Associate Director, Brand Analytics, CNS Pipeline

Otsuka Pharmaceutical Companies (U.S.)

Princeton, NJ (On-site)

$169K/yr - $253K/yrIn-houseFull-timeSenior level6+ years exp.
4 months ago
Otsuka Pharmaceutical Companies (U.S.) logo
Otsuka Pharmaceutical Companies (U.S.)

Executive Director, Omnichannel & Content Operations

Princeton, NJ (On-site)

$250K/yr – $388K/yrSenior Level12+ years expFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own omnichannel strategy and content operations for healthcare brands, turning data and AI into real-time customer journeys across digital and offline touchpoints.

  • Omnichannel Leadership: Align brands with a scalable engagement strategy and cross-functional execution from planning through measurement.
  • Content and AI Ops: Build modular content, automated decisioning, and a high-velocity content factory to power personalized journeys.

Job Description

Own end-to-end omnichannel customer engagement and content delivery across brands, aligning with field execution and cross-functional partners.

  • Lead therapeutically aligned omnichannel business partners to partner with brands in developing and activating brand customer engagement strategies.
  • Define and lead the omnichannel engagement strategy, ensuring seamless, personalized customer experiences across digital and offline touchpoints
  • Guide cross-functional planning to integrate brand objectives with omnichannel capabilities and field execution.
  • Collaborate with insights, analytics, and field teams to define KPIs and continuously optimize customer journeys.
  • Implement workflows, tools, and governance to optimize throughput, efficiency, and asset lifecycle management.
  • Lead the development and deployment of advanced predictive analytics capabilities to optimize targeting, personalization, and journey orchestration.
  • Oversee the design and operation of decision engines (e.g., next best action/content) powered by AI/ML and customer data platforms.
  • Partner with data science and analytics teams to translate insights into actionable marketing strategies and automated decisioning.
  • Build and manage a high-performing content factory to deliver high-volume, high-quality marketing assets at speed and scale.
  • Oversee modular content development, enabling reuse, personalization, and dynamic assembly across channels.
Otsuka Pharmaceutical Companies (U.S.) logo

Otsuka Pharmaceutical Companies (U.S.)

There are two Otsuka pharmaceutical industry companies in the U.S.:Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America.Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.

Founded in 1989
Princeton, New Jersey, USA
3.6K employees (162 in marketing)
www.otsuka-us.com

Traffic Signals

Monthly Visitors
118K
Traffic Source Mix
Search
35.5%
Direct
56%
Referral
6.7%
Social
1%
Paid
0.7%

Headcount Trend

Current headcount: ~3.6K

Marketing Team

Marketing Team Size
141 (4% of company)
Median Career Experience
17 years
Median Tenure
3.6 years

People

HR / Recruitment

Rich Dunn
Rich Dunn
Head of Talent Acquisition
At the company for 6 years 5 months
Phuong Le Muller
Phuong Le Muller
Director Talent Acquisition
At the company for 5 months

Marketing Leadership

RJ Lasek
RJ Lasek
Vice President, Marketing and Portfolio Strategy
At the company for 1 year 9 months
Neveen Abou-Gharbia, PharmD, MBA
Neveen Abou-Gharbia, PharmD, MBA
Executive Director, CNS Marketing Brand Head (MDD)
At the company for 15 years 2 months
Rich Dunn
Rich Dunn
Head of Talent Acquisition
At the company for 6 years 5 months
Dianel McLoughlin
Dianel McLoughlin
Director HCP Marketing - ADHD
At the company for 5 months

Recent News

Otsuka’s IgAN therapy gets a thumbs-up from the FDA
Nov 26, 2025 • BioWorld MedTech
Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression
Nov 26, 2025 • BioSpace
US FDA approves Otsuka’s drug for a type of kidney disease
Nov 25, 2025 • pharmalive.com
FDA approves Otsuka kidney disease therapy
Nov 25, 2025 • statnews.com
US FDA approves Otsuka's drug for a type of kidney disease
Nov 25, 2025 • Reuters
Otsuka files for US approval for centanafadine in ADHD
Nov 25, 2025 • The Pharma Letter
Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
Nov 25, 2025 • BioSpace
FDA turns down Lundbeck, Otsuka's Rexulti in PTSD on lack of efficacy data
Sep 22, 2025 • Fierce Pharma
Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD
Sep 20, 2025 • News Powered by Cision
Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD
Sep 20, 2025 • Reuters
Rare Kidney Disease Community Members Join American Kidney Fund and IgA Nephropathy Foundation on Capitol Hill to Champion Key Legislation
Sep 11, 2025 • American Kidney Fund
Bipolar Disorder Market Research Report 2025-2035 | Pharma Leaders Advance Bipolar Disorder Treatment with Targeted Therapies and Genomic Innovation
Jul 21, 2025 • Research and Markets
Otsuka Pharmaceutical acquires Cantargia's CAN10 program in a deal worth over USD 600 million
Jul 17, 2025 • Biostock
Otsuka Pharmaceutical acquires Cantargia's CAN10 program in a deal worth over $600 million
Jul 17, 2025 • Biostock
FDA staff raises efficacy concerns for Otsuka's PTSD combination treatment
Jul 16, 2025 • Reuters
Schizophrenia Market Research and Forecast Report 2025-2034 | Emerging Therapies and Genetic Research Drive Growth with Bristol Myers Squibb, AstraZeneca, and Eli Lilly Leading
Jul 8, 2025 • GlobeNewswire News Room
Alzheimer’s Drugs Market to witness 20% CAGR due to increased diagnosis and drug innovation by 2029
Jul 7, 2025 • PharmiWeb
Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
May 27, 2025 • BioSpace
PBS and WETA Caregiving Documentary by Executive Producer Bradley Cooper Now Available to Stream
May 27, 2025 • Business Wire
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
May 1, 2025 • Stock Titan
Phenylketonuria Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight
Apr 29, 2025 • DelveInsight Business Research LLP
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Apr 1, 2025 • BioSpace
Otsuka debuts new kid-friendly resources about Alzheimer's to ease burden on 'sandwich generation' caregivers
Mar 7, 2025 • Fierce Pharma
Parenteral Nutrition Market Size to Hit $11.12 Billion, Globally, by 2030 | Exclusive Report by The Insight Partners
Mar 3, 2025 • PR Newswire
Parenteral Nutrition Market Size to Hit $11.12 Billion, Globally, by 2030 | Exclusive Report by The Insight Partners
Mar 3, 2025 • prnewswire.co.uk
JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Dec 19, 2024 • BioSpace
JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Dec 18, 2024 • Morningstar, Inc.
JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Dec 18, 2024 • Business Wire
Cutaneous T-Cell Lymphoma Market to Evolve Rapidly from 2024 to 2034 | DelveInsight | Angimmun, Philogen, Soligenix
Dec 17, 2024 • EIN Presswire
The National Hispanic Health Foundation (NHHF) Hosts Scholarship Gala in Washington, DC to Honor Leaders and Students Advancing Health Equity
Dec 3, 2024 • PR Newswire
Approval Sought in Japan for New Drug to Lower Cholesterol Research Report
Dec 3, 2024 • streetwisereports.com
Otsuka, ICU Medical form joint venture to boost IV solution supply in North America
Nov 14, 2024 • Fierce Pharma
CEO of Otsuka North America: Are We Getting better access with AI?
Nov 14, 2024 • MedCity News
Otsuka and ICU Medical forge IV manufacturing network to supply the US
Nov 13, 2024 • Endpoints News
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a Subsidiary of Otsuka Holdings Co. Ltd., Announce Creation of a Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
Nov 12, 2024 • PR Newswire
Otsuka Funds Grants to Address Mental Health Inequities in NJ Communities
Oct 29, 2024 • New Jersey Business & Industry Association
Merck Sharp & Dohme and Otsuka Pharmaceutical discover TP53 mutant activators
Sep 26, 2024 • http://www.zdnet.com/
CIB exits investment in Egypt Otsuka Pharmaceuticals, selling stake to Otsuka Group
Aug 21, 2024 • Daily News Egypt
Otsuka Pharmaceutical patents new antibody-drug conjugates
Aug 13, 2024 • http://www.zdnet.com/
Healthcare And AI Sectors Continue To Lead, While Funding Settles In July 2024
Aug 7, 2024 • Crunchbase News
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
Aug 1, 2024 • Globe Newswire
Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for ...
Jun 26, 2024 • Business Wire
Global Smart Pills Market Size To Worth USD 1.5 Billion By 2033 | CAGR Of 11.61%
Jun 22, 2024 • GlobeNewswire
Otsuka expands licensing deal for donidalorsen | The Pharmaletter
Jun 20, 2024 • The Pharma Letter
Ionis Pharmaceuticals, Inc. Announces Expand Licensing Agreement with Otsuka Pharmaceutical Co., Ltd
Jun 18, 2024 • MarketScreener
Otsuka Launches New Company to Commercialize Rejoyn, the First Digital Therapeutic for Depression
May 28, 2024 • MedCity News
Otsuka sponsors Bradley Cooper-produced documentary film about caregivers
May 28, 2024 • Fierce Pharma
Otsuka Drops Alzheimer’s Agitation Drug Following Phase III Failure
May 27, 2024 • BioSpace
Otsuka America, Inc’s. Data and Technology Company will Support Rejoyn™ Commercialization & Personalized Patient Engagement
May 6, 2024 • Business Wire
Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic
Apr 21, 2024 • STAT
Otsuka, Click Therapeutics get FDA clearance for prescription digital therapeutic
Apr 21, 2024 • MobiHealthNews
Glaucoma Market to witness growth by 2034, estimates DelveInsight | Allergan, Santen Pharmaceutical, Kowa
Apr 4, 2024 • EIN News
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the ...
Apr 1, 2024 • Business Wire
Proteus CEO talks regulation hurdles, future plans for digital pill
Jan 1, 1970 • Mobil Health News
Mindset Pharma to be acquired by unit of healthcare company Otsuka Pharmaceutical
Jan 1, 1970 • SeekingAlpha
News - Focus On, Medimetriks Pharmaceuticals
Jan 1, 1970 • The Pharma Letter
Schizophrenia Market is Expected to Showcase a Significant ...
Jan 1, 1970 • GlobeNewswire
Daiya appoints Hajime Fujita as Chief Executive Officer
Jan 1, 1970 • PR Newswire
Court approves Otsuka’s bid to buy Proteus for $15M
Jan 1, 1970 • MedCity News